Gonorrhoea: Drug Resistance in Australia

Australian Federation of AIDS Organisations (AFAO), 26 June 2018

There has long been concern globally about the potential emergence of drug resistant STIs. In response, the World Health Organisation released new treatment guidelines for three common STIs – chlamydia, gonorrhoea and syphilis – in 2016.

At present, strains resistant to first line treatment of syphilis and chlamydia are not common and not a concern in Australia. There is, however, a growing level of concern about gonorrhoea. This paper therefore focuses on the likelihood and implications of the emergence of drug resistant cases of gonorrhoea in Australia. It also highlights treatment options in Australia and current and emerging strategies for preventing drug resistant gonorrhoea.

Download paper: AFAO Brief – Gonorrhoea – Drug Resistance in Australia – 26 June 2018

Gonorrhoea ‘super-superbugs’ triple in six months [in Australia]

SMH, 13/02/2018

Cases of a strain of gonorrhoea impervious to an antibiotic have almost tripled in six months, the latest report from the National Alert System for Critical Antimicrobial Resistance (CARAlert) reveals.

The result was a “warning shot across the bow” for doctors and public health officials fighting antibiotic resistance, CARAlert’s senior medical adviser said.

Vaccine for Meningitis Shows Some Protection Against Gonorrhea

New Zealand Family Planning

Some strains of the bacterium that cause gonorrhoea are now resistant to all available antibiotics. With no new drugs on the near horizon, the disease is in desperate need of a vaccine.

Our research, published in the Lancet medical journal this week, shows that protection against gonorrhoea could come from an unexpected source – a vaccine against meningococcal group B disease.

 

 

 

Early warning system exposes the rise of the gonorrhoea ‘super-superbug’

The Age, July19th 2017 – 8:32 AM

A critically drug-resistant strain of gonorrhoea dubbed a “super-superbug” has been detected in every Australian state and territory by a new national surveillance system.

The National Alert System for Critical Antimicrobial Resistance (CARAlert) identified 1,064 bacteria highly resistant to last-line antibiotics between 17 March 2016 and 31 March 2017 across 73 laboratories.

Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in SA

The Lancet Infectious Diseases, 17 (2), February 2017

Abstract:

Antimicrobial resistance in Neisseria gonorrhoeae is recognised globally as a public health threat. Dual therapy with ceftriaxone and azithromycin has been introduced in Australia and elsewhere as the first-line treatment recommendation for gonorrhoea. While there have been only sporadic reports of ceftriaxone-resistant gonococci, globally there have been increasing reports of N gonorrhoeae resistance to azithromycin.1 The Australian Gonococcal Surveillance Programme2 is one of the most comprehensive N gonorrhoeae antimicrobial resistance surveillance programmes worldwide.